Expression of EpCAM Increases in the Hepatitis B Related and the Treatment-Resistant Hepatocellular Carcinoma

Table 1

Clinical profiles of 58 hepatocellular carcinoma patients. They had surgery without previous treatment.

	HBV	HCV	NBNC
Number	18	23	17
Age	56.0±10.1	65.6±8.3	69.8±8.0	𝑝=0.0003
Sex (male/female)	14/4	15/8	15/2	𝑝=0.2369
Differentiation (wel/mod/por)	2/12/4	4/12/5	5/7/5	𝑝=0.7967
Tumor size (mm)	53.3±52.3	42.3±25.1	66.2±42.3	𝑝=0.0756
ALT (IU/L)	61.1±37.3	60.5±48.7	32.6±34.0	𝑝=0.0027
γGTP (IU/L)	98.2±86.8	79.3±70.2	114.8±153.3	𝑝=0.9223
Alb (g/dL)	4.1±0.3	4.0±0.4	4.0±0.3	𝑝=0.5170
Plt (×10^3/𝜇L)	161.2±43.6	160.6±48.2	213.6±78.9	𝑝=0.0932
AFP (ng/mL)	1630.9±2743.8	961.6±2956.0	2717.8±10983.9	𝑝=0.1753
AFP-L3 (%)	18.2±22.7	16.0±20.1	14.1±23.9	𝑝=0.4964
PIVKA-II (AU/L)	48377.1±132988.9	10912.2±43623.6	16646.0±39322.3	𝑝=0.5643

Data expressed as mean ± SD. ALT: alanine aminotransferase; γGTP: γ-glutamyl transpeptidase; Alb: albumin; Plt: platelet; AFP: alpha-fetoprotein; AFP-L3 (%): LCA-reactive alpha-fetoprotein isoform; PIVKA-II: protein induced by vitamin K absence or antagonists-II. Sex and differentiation analyzed by 𝜒² test. Other data analyzed by Kruskal-Wallis test.